BHST logo

BIOHARVEST SCIENCES INC

BHSTNASDAQ
US Equity
$888.98▲ $78.94 (+8.88%)
Simulated price
🔔
Track BHST
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 8.9%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$399.03B
Large Cap
📈Revenue Growth (YoY)
+111.7%
High Growth
📊Gross Margin
54.0%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
2.7x
Cheap
Otter Score
72
Fair
No chart data available for BHST.

Trading Snapshot

Day Range
$875.61 – $896.02
52-Week Range
$0.14 – $0.38
Volume
$4.79B
Avg Volume
$5.98B
Shares Outstanding
22.7M
Next Earnings
Nov 3, 2026

Fundamentals Snapshot

Annual Revenue
$35M
Last Q Revenue
$9M
P/E Ratio
—
P/S Ratio
2.7x
EPS (TTM)
$-1.19
Dividend Yield
—
Dilution (1yr)
+6.3%

Why Investors Own BHST

  • ✓High-growth profile — revenue up +24.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 48% gross margin and 24% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BHST logo

BIOHARVEST SCIENCES INC

BHST
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$35M▲ +37.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
59.3%▲ +7.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$6M▼ −20.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$10M▲ +0.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
18.4M▲ +6.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$9M▲ +$20M YoY
StockOtter · stockotter.space

About BIOHARVEST SCIENCES INC

BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals. A key innovation is its proprietary botanical synthesis platform technology, which allows for the cultivation of active ingredients found within plant enzymes or cells. The company harnesses this advanced technology to craft evidence-based and clinically validated therapeutic products for both its nutraceutical and pharmaceutical offerings. Beyond its own development, it also provides contract development and manufacturing services. Its product portfolio includes various wellness items, notably VINIA, a dietary supplement derived from red grape cells, which delivers the full spectrum of polyphenols naturally present in red grapes. The company conducts business in Israel and the United States, with its corporate base in Vancouver, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$924.43
▲ +4.0% Upside
High Target$1,115.07
Low Target$844.40
Based on 26 analysts

Latest News & Updates

🚀
Barron’s·2h ago

BIOHARVEST SCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift BHST price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

BIOHARVEST SCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.